Download this whitepaper to learn more.
As precision oncology transitions towards a targeted pan-tumor approach, comprehending prevalence rates and testing patterns becomes crucial for commercial success and adoption. Tumor-agnostic clinical trials might not completely grasp the clinical implications of treatment and efficacy due to patient diversity, underscoring the importance of real-world data to glean insights across various patient subgroups. With the innovative approach of targeting RET-rearranged tumors, we investigated the current landscape of RET testing to uncover both challenges and opportunities associated with this new pan-tumor indication. In this white paper, you will discover:
The power of linking detailed genomic data to medical claims to enhance outcomes measures in specific patient-populations.
Offered Free by: NeoGenomics
See All Resources from: NeoGenomics